1. Males and females ≥ 12 years of age.

2. Clinical diagnosis of type 1 diabetes for at least 12 months according to the Diabetes Canada Clinical Practice Guidelines Expert Committee diagnostic criteria.

3. The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.

4. Insulin pump therapy for at least 6 months.

5. HbA1c ≤ 12%.

1. Current or ≤ 1 month use of other antihyperglycemic agents (SGLT2 (Sodium-glucose Cotransporter-2), GLP-1 (glucagon-like peptide 1), Metformin, Acarbose, etc.…).

2. Current use of glucocorticoid medication.

3. Use of medication that alters gastrointestinal motility.

4. Planned or ongoing pregnancy.

5. Breastfeeding individuals.

6. Severe hypoglycemic episode within one month of admission.

7. Severe diabetes keto-acidosis episode within one month of admission.

8. Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator.

9. Recent (< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.

10. Known hypersensitivity to any of the study drugs or their excipients.

11. Individuals with hypoglycemia unawareness.

12. Individuals with confirmed gastroparesis.

13. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.

14. Failure to comply with team's recommendations (e.g. not willing to eat meals/snacks, not willing to change pump parameters, etc.).

Study Discontinuation/Withdrawal

1. Failure to comply with the protocol.

2. Pregnancy.

3. After an event which the PI believes it is not in the best interest for the patient to continue the trial.